도심항공모빌리티 비행체 PAV 탑승자 실내행위에 영향을 미치는 제약 요소 도출 및 인체 영향 수준에 따른 설계 기준

진석준,오영훈,주다영 한국감성과학회 2022 감성과학 Vol.25 No.-

최근 도심항공모빌리티(UAM) 상용화에 앞서 도심 내 항공 교통수단 관련 산업에 대한 연구개발 중요성이 급격히 증가하고 있다. 도심항공모빌리티(UAM) 환경을 조성하기 위해서 핵심 항공 이동 수단 비행체인 개인용 항공기 (PAV) 기체에 관한 연구가 수행되고 있으나, 탑승자 관점의 연구가 상대적으로 부족한 상황이다. 특히 PAV는 탑승 자의 새로운 생활공간으로 활용될 것으로 예상되기 때문에 탑승자의 실내행위를 지원하는 실내공간 설계를 위해서 는 PAV 기체에서 발생하는 물리적 요소가 인체에 미치는 영향에 관한 연구가 필수적으로 이루어져야 한다. 이에 본 연구의 목적은 PAV의 공중 운항 특성으로 인해 인체에 영향을 주는 제약 요소를 도출하고, 이러한 제약 요소가 실내행위를 수행하는 탑승자 인체에 미치는 영향을 파악하는 것이다. 본 연구 결과, 항공 이동 수단 비행 기체 PAV 는 4,000ft 이하에서 운항해야 하는 기준에 따라, 운항고도에 따른 제약 요소는 소음, 진동, 저주파 운동에 의한 멀미 로 나타났다. 이러한 제약 요소가 실내행위에 영향을 미친다는 관점에서 PAV에서 행할 수 있는 실내행위를 자율주 행 자동차, 비행기, PAV 컨셉 사례를 활용하여 도출하고 인체에 미치는 영향과 수준을 고려하여 실내행위 지원을 위한 제약 요소 권장기준을 설정하였다. 또한 실내행위 지원을 위한 제약 요소의 인체 영향 수준을 감소시키기 위해 서는 시트의 형태 및 내장기능(진동 저감 기능, 온도조절, LED조명 등), 개인 좌석별 지향성 스피커를 활용한 외부소 음 감소, 소음과 진동 감소를 위한 내장재 등을 실내공간 설계에 반영해야 함을 제시하였다. 본 연구는 PAV 실내행 위에 영향을 주는 제약 요소를 도출하였고, 인체에 미치는 영향 수준을 확인하였으며, 추후 PAV 실내 설계 시 기초 자료로써 활용할 수 있다는 점에서 의미가 있다. Recently, prior to the commercialization of urban air mobility (UAM), the importance of R&D for air transportation-related industries in urban areas has significantly increased. To create a UAM environment, research is being conducted on personal air vehicles (PAVs). They are key means of air transportation, but research on the physical factors influencing their passengers is relatively insufficient. In particular, because the PAV is expected to be used as a living space for the passengers, research on the effects of the physical elements generated in the PAV on the human body is essential to design an interior space that supports the in-vehicle activities of the passengers. Therefore, the purpose of this study is to derive the constraint factors that affect the human body due to the air navigation characteristics of the PAV and to understand the impact of these constraint factors on the bodies of the passengers performing in-vehicle activities. The results of this study indicate that when the PAV was operated at less than 4,000 ft, which is the operating standard, the constraint factors were noise, vibration, and motion sickness caused by low-frequency motion. These constraint factors affect in-vehicle activity; thus, the in-vehicle activities that can be performed in a PAV were derived using autonomous cars, airplanes, and PAV concept cases. Furthermore, considering the impact of the constraint factors and their levels on the human body, recommended constraint factor criteria to support in-vehicle activities were established. To reduce the level of impact of the constraint factors on the human body and to support in-vehicle activity, the seat's shape and built-in functions of the seat (vibration reduction function, temperature control, LED lighting, etc.) and external noise reduction using a directional speaker for each individual seat were recommended. Moreover, it was suggested that interior materials for noise and vibration reduction should be used in the design of the interior space. The contributions of this study are the determination of the constraint factors affecting the in-vehicle PAV activity and the confirmation of the level of impact of the factors on the human body; in the future, these findings can be used as basic data for suitable PAV interior design.

도심항공모빌리티 비행체 PAV 탑승자 실내행위에 영향을 미치는 제약 요소 도출 및 인체 영향 수준에 따른 설계 기준

진석준,오영훈,주다영 한국감성과학회 2022 감성과학 Vol.25 No.1

Recently, prior to the commercialization of urban air mobility (UAM), the importance of R&D for air transportation-related industries in urban areas has significantly increased. To create a UAM environment, research is being conducted on personal air vehicles (PAVs). They are key means of air transportation, but research on the physical factors influencing their passengers is relatively insufficient. In particular, because the PAV is expected to be used as a living space for the passengers, research on the effects of the physical elements generated in the PAV on the human body is essential to design an interior space that supports the in-vehicle activities of the passengers. Therefore, the purpose of this study is to derive the constraint factors that affect the human body due to the air navigation characteristics of the PAV and to understand the impact of these constraint factors on the bodies of the passengers performing in-vehicle activities. The results of this study indicate that when the PAV was operated at less than 4,000 ft, which is the operating standard, the constraint factors were noise, vibration, and motion sickness caused by low-frequency motion. These constraint factors affect in-vehicle activity; thus, the in-vehicle activities that can be performed in a PAV were derived using autonomous cars, airplanes, and PAV concept cases. Furthermore, considering the impact of the constraint factors and their levels on the human body, recommended constraint factor criteria to support in-vehicle activities were established. To reduce the level of impact of the constraint factors on the human body and to support in-vehicle activity, the seat's shape and built-in functions of the seat (vibration reduction function, temperature control, LED lighting, etc.) and external noise reduction using a directional speaker for each individual seat were recommended. Moreover, it was suggested that interior materials for noise and vibration reduction should be used in the design of the interior space. The contributions of this study are the determination of the constraint factors affecting the in-vehicle PAV activity and the confirmation of the level of impact of the factors on the human body; in the future, these findings can be used as basic data for suitable PAV interior design. 최근 도심항공모빌리티(UAM) 상용화에 앞서 도심 내 항공 교통수단 관련 산업에 대한 연구개발 중요성이 급격히 증가하고 있다. 도심항공모빌리티(UAM) 환경을 조성하기 위해서 핵심 항공 이동 수단 비행체인 개인용 항공기 (PAV) 기체에 관한 연구가 수행되고 있으나, 탑승자 관점의 연구가 상대적으로 부족한 상황이다. 특히 PAV는 탑승 자의 새로운 생활공간으로 활용될 것으로 예상되기 때문에 탑승자의 실내행위를 지원하는 실내공간 설계를 위해서 는 PAV 기체에서 발생하는 물리적 요소가 인체에 미치는 영향에 관한 연구가 필수적으로 이루어져야 한다. 이에 본 연구의 목적은 PAV의 공중 운항 특성으로 인해 인체에 영향을 주는 제약 요소를 도출하고, 이러한 제약 요소가 실내행위를 수행하는 탑승자 인체에 미치는 영향을 파악하는 것이다. 본 연구 결과, 항공 이동 수단 비행 기체 PAV 는 4,000ft 이하에서 운항해야 하는 기준에 따라, 운항고도에 따른 제약 요소는 소음, 진동, 저주파 운동에 의한 멀미 로 나타났다. 이러한 제약 요소가 실내행위에 영향을 미친다는 관점에서 PAV에서 행할 수 있는 실내행위를 자율주 행 자동차, 비행기, PAV 컨셉 사례를 활용하여 도출하고 인체에 미치는 영향과 수준을 고려하여 실내행위 지원을 위한 제약 요소 권장기준을 설정하였다. 또한 실내행위 지원을 위한 제약 요소의 인체 영향 수준을 감소시키기 위해 서는 시트의 형태 및 내장기능(진동 저감 기능, 온도조절, LED조명 등), 개인 좌석별 지향성 스피커를 활용한 외부소 음 감소, 소음과 진동 감소를 위한 내장재 등을 실내공간 설계에 반영해야 함을 제시하였다. 본 연구는 PAV 실내행 위에 영향을 주는 제약 요소를 도출하였고, 인체에 미치는 영향 수준을 확인하였으며, 추후 PAV 실내 설계 시 기초 자료로써 활용할 수 있다는 점에서 의미가 있다.

건강한 성인 남성에서 아나스트로졸의 집단약동학 분석

노육환,고영주,정진아,김운집,진석준,황애경,박현정,배균섭,임형석 대한임상약리학회 2010 Translational and Clinical Pharmacology Vol.18 No.1

Aims: This study was aimed to characterize the population pharmacokinetics of Arimidex® (anastrozole) which has been administered to healthy Korean male volunteers. Methods: We have committed population pharmacokinetic analysis using NONMEM® VII with 408 plasma concentration data obtained from subjects who were administered with reference drug Arimidex® in a randomized, double-blind, two-way crossover bioequivalence trial conducted in Asan Medical Center. We estimated the parameters by first-order conditional estimation (FOCE) method, and then, observed the change of objective function values which had been calculated by using different compartment models, and explored the significant covariates. To evaluate the suitability and stability of final population model, we performed bootstrapping and visual/numerical predictive checks using Wings for NONMEM and Perl-speaks-NONMEM software. We simulated the plasma concentration corresponding to daily doses of anastrozole 1 mg through 10 days. Results: The plasma concentration data of Arimidex® is best fitted by first-order two-compartment linear model. The estimated absorption rate constant value is 0.23 h-1, and the final estimates for the volume of distribution of central and peripheral compartment is calculated as 5.12 L and 319 L,respectively. Conclusions: We successfully constructed the final population pharmacokinetic model of Arimidex® in this study, which could be useful for various purposes such as Monte-Carlo simulation for the plasma concentration-time profiles of Arimidex®.

SI 가솔린 엔진의 과급 및 흡기가 엔진 성능에 미치는 영향에 대한 연구

김기복(Gi-Bok Kim),진석준(Seok-Jun Jin),김치원(Chi-Won Kim),윤창식(Chang-Sik Yoon),한성현(Sung-Hyun Han) 한국산업융합학회 2015 한국산업융합학회 논문집 Vol.18 No.2

In this study, it is designed and used the test engine bed which is installed with turbocharger, and in addition to equipped using by oxygen adder. It has been controlled the oxygen volumetric fraction of intake air chrge, and supercharged flow rate into the cylinder of SI 4-stroke engine, and then, has been analyzed engine performance, combustion characteristics, and exhaust emission as analysis parameters. The tested parameters were the oxygen fraction and the variation of engine speed and air-fuel ratio.

Comparison of Pharmacokinetics and Safety of Two Formulations of Letrozole (2.5 mg) in Healthy Male Volunteers

노육환,배균섭,조상헌,최상민,김종률,정진아,김운집,진석준,박현정,김정철,임형석,Noh, Yook-Hwan,Bae, Kyun-Seop,Cho, Sang-Heon,Choe, Sangmin,Ghim, Jong-Lyul,Jung, Jin Ah,Kim, Un-Jib,Jin, Seok-Joon,Park, Hyun-Jung,Kim, Jung-Chul,Lim, Hyeon Korean Society for Clinical Pharmacology and Thera 2012 臨床藥理學會誌 Vol.20 No.2

배경: 레트로졸은 유방암 치료에 사용되는 경구용 비스테로이드성 aromatase 억제제이다. 방법: 이 연구는 건강한 성인 남성을 대상으로 무작위 배정, 단회 투여, 공개설계로서 두 치료군, 두 순서, 두 시기의 교차 시험법으로 진행되었다. 각 순서군에 13명씩 무작위 배정되어, 한군은 1기에 페마라$^{(R)}$정(대조약)을, 2기에 유한 레트로졸정(시험약)을, 다른 한군은 반대 순서로 두 시기 사이에 약 5주의 휴약기를 가지고 각각 2.5 mg정 1정씩 투여 받았다. 약동학 분석을 위한 혈액 검체는 공복 상태에서 투약 후 312 시간까지 얻어졌다. 레트로졸의 혈장 내 농도는 liquid chromatography-tandem mass spectrometry를 이용하여 측정하였다. 안전성 평가는 활력징후, 문진 및 신체검사, 심전도, 진단검사실 검사와 이상반응 모니터링을 통하여 이루어졌다. 결과: 총 26명의 피험자가 연구를 완료하였고, 약동학 분석에 26명의 자료가 모두 사용되었다. $C_{max}$와 $AUC_{last}$ 파라미터에 대한 시험약과 대조약의 기하평균비는 각각 0.92 (90 % 신뢰구간: 0.85 - 0.99)와 1.01 (90 % 신뢰구간: 0.97 - 1.04)였다. 보고된 중대한 이상반응은 없었으며, 임상적으로 유의한 변화도 관찰되지 않았다. 결론: 건강한 자원자에서 페마라$^{(R)}$정과 유한 레트로졸정의 약동학 특성과 안전성은 유사하였다. Background: Letrozole is an oral non-steroidal inhibitor of the aromatase enzyme, which has proven to be a useful drug against breast cancer. Methods: This single-dose, randomized $2{\times}2$ crossover study was conducted in healthy male volunteers. Participants of each sequence group (each 13 volunteers for sequence group) received, in randomized sequence, a single oral 2.5-mg dose of generic letrozole (test) or branded letrozole (reference). Each treatment period was separated by a 5-week washout period. Blood samples were collected for up to 312 hours after drug administration, and drug concentrations were determined using validated LC/MS-MS. Pharmacokinetic properties were obtained using noncompartmental analysis. Drug tolerability was assessed throughout the study, using measurements of vital signs, physical examination, clinical chemistry testing, EKG, and interviews. Results: A total of 26 subjects completed the study. The geometric mean ratios (90% CI) of $C_{max}$ and $AUC_{last}$ were 0.92 (0.85 - 0.99) and 1.01 (0.97 - 1.04), respectively. No serious AEs were reported, and there were no clinically significant differences between test and reference groups. Conclusion: The findings from this study suggest bioequivalence between two formulations of letrozole in healthy male volunteers. The safety profile of two formulations had similar characteristics.

Development of a validated liquid chromato-graphy–tandem mass spectrometry assay for the quantification of simvastatin acid, the active metabolite of simvastatin, in human plasma

박현정,황애경,김아름,김수현,김은화,조상헌,김종률,최상민,정진아,진석준,배균섭,임형석 대한임상약리학회 2016 Translational and Clinical Pharmacology Vol.24 No.1

Simvastatin is a lipid-lowering drug that is metabolized to its active metabolite simvastatin acid (SA). We developed and validated a sensitive liquid chromatography–tandem mass spectrometry (LC/MS/MS) method to quantitate SA in human plasma using a liquid–liquid extraction method with methanol. The protonated analytes generated in negative ion mode were monitored by mul-tiple reaction monitoring. Using 500-mL plasma aliquots, SA was quantified in the range of 0.1–100 ng/mL. Calibration was performed by internal standardization with lovastatin acid, and regression curves were generated using a weighting factor of 1/x². The linearity, precision, and accuracy of this assay for each compound were validated using quality control samples consisting of mixtures of SA (0.1, 0.5, 5, and 50 ng/mL) and plasma. The intra-batch accuracy was 95.3–107.8%, precision was –2.2% to –3.7%, and linearity (r²) was over 0.998 in the standard calibration range. The chromato¬graphic running time was 3.0 min. This method sensitively and reliably measured SA concentra¬tions in human plasma and was successfully used in clinical pharmacokinetic studies of simvastatin in healthy Korean adult male volunteers.